Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with healthy controls. A comparison of the second-generation Bruton tyrosine ...

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The indication applies to use of the agent in adults ...

In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of certain patients with relapsed ...

Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I.

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape.

Eli Lilly and Co., through its Loxo@Lilly oncology unit, secured its second accelerated approval for non-covalent Bruton’s tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib), this time to treat ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of ...

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...